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Molecular detection of fungal 
pathogens in clinical specimens 
by 18S rDNA high-throughput 
screening in comparison to ITS PCR 
and culture
K. Wagner1, B. Springer2, V. P. Pires1 & P. M. Keller  1
The rising incidence of invasive fungal infections and the expanding spectrum of fungal pathogens 
makes early and accurate identification of the causative pathogen a daunting task. Diagnostics using 
molecular markers enable rapid identification of fungi, offer new insights into infectious disease 
dynamics, and open new possibilities for infectious disease control and prevention. We performed a 
retrospective study using clinical specimens (N = 233) from patients with suspected fungal infection 
previously subjected to culture and/or internal transcribed spacer (ITS) PCR. We used these specimens 
to evaluate a high-throughput screening method for fungal detection using automated DNA extraction 
(QIASymphony), fungal ribosomal small subunit (18S) rDNA RT-PCR and amplicon sequencing. Fungal 
sequences were compared with sequences from the curated, commercially available SmartGene IDNS 
database for pathogen identification. Concordance between 18S rDNA RT-PCR and culture results 
was 91%, and congruence between 18S rDNA RT-PCR and ITS PCR results was 94%. In addition, 18S 
rDNA RT-PCR and Sanger sequencing detected fungal pathogens in culture negative (N = 13) and ITS 
PCR negative specimens (N = 12) from patients with a clinically confirmed fungal infection. Our results 
support the use of the 18S rDNA RT-PCR diagnostic workflow for rapid and accurate identification of 
fungal pathogens in clinical specimens.
In recent years an enormous increase in the frequency and severity of fungal infections has been observed1,2. 
Medical progress has also contributed to increased opportunistic infections in patients, who are immunocom-
promised or who are infected during intensive care treatment3. Rapid diagnosis of fungal infections is a key 
factor for patient outcome4. Traditionally, diagnosis of fungal infection has relied primarily on direct microscopic 
examination of clinical samples, histopathology and culture5,6. However, diagnostic performance of microscopic 
examination and culture are highly dependent on the quality of the clinical specimens and the experience of 
the laboratory personnel. Moreover, these classical methods have previously shown lower sensitivity in fungal 
detection compared to molecular methods7–9. PCR based assays do not require viable cells and have the power to 
identify the continuously increasing number of fungi that are clinically relevant pathogens in humans, including 
rarely encountered species9,10. Fungal ribosomal genes are multicopy targets, facilitating an efficient detection 
using PCR, while the conserved nature of the 18S rRNA gene enables accurate sequence identification11,12. One 
limitation for the evaluation of new diagnostic methods remains the lack of a gold standard as culture and micro-
scopic examination have been proven to be less sensitive than PCR based methods7–9,13. Therefore, a more appro-
priate approach is a compilation of clinical and microbiological data as gold standard to evaluate the diagnostic 
performance of new molecular methods.
In this retrospective study, we used clinical specimens that have been previously analysed by culture and/or 
internal transcribed spacer (ITS) PCR and could be categorized as “confirmed fungal infection” or “no fungal 
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infection”. These specimens were retrospectively analysed by RT-PCR amplification of the fungal ribosomal small 
subunit (18S) and amplicon sequencing to rapidly and accurately identify fungal pathogens (Fig. 1).
Results
Diagnostic performance of 18S rDNA RT-PCR compared to ITS PCR. In total, 233 clinical samples 
were retrospectively analyzed, of those 143 specimens (61%) concordantly tested negative and 76 specimens 
(33%) tested positive by ITS and 18S rDNA sequencing. Fourteen of 233 clinical specimens (6%) showed discrep-
ant results between both methods (Tables 1 and 2).
Sixty-five of 233 clinical specimens revealed no cycling threshold (Ct) value in the 18S rDNA RT-PCR and 
were therefore assessed negative. 168/233 showed amplification with a Ct value in the 18S rDNA RT-PCR. In 14 
Figure 1. Overview of the diagnostic algorithms used for identification of fungal pathogens at the Institute of 
Medical Microbiology, University of Zurich.
clinical and microbiological data
positive negative
18S rDNA RT-PCR
positive 88a 0
negative 2 143
ITS PCR
positive 78a 0
negative 12 143
Table 1. Comparison of fungal identification by 18S rDNA RT-PCR and ITS PCR (N = 233) applying a gold 
standard that combines clinical and microbiologal data. a76 clinical specimens were congruently tested positive 
by both methods.
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of those specimens, known environmental contaminants were identified (e.g Funneliformis mosseae, Stereocaulon 
urceolatum; Table S1), 64 specimens showed no fungal identification (i.e weak peaks or multiple overlying peaks 
in the Sanger electropherograms), and in 88 specimens a fungal pathogen was identified. In 62/233 specimens, 
no distinct ITS PCR fragment was visible in the CleanGel, and these specimens were assessed negative. 171/233 
specimens showed an ITS PCR amplification product in the CleanGel. In 81 of those specimens, fungal identifi-
cation was not possible or revealed known environmental contaminants, while in 78 specimens fungal pathogens 
were identified.
A diverse range of fungal genera were concordantly identified by ITS PCR and 18S rDNA RT-PCR, including 
Aspergillus, Candida, Cryptococcus, Fusarium, Lichtheimia, Penicillium, Scedosporium, Rhizomucor and Rhizopus. 
The five most prevalent fungal genera identified were Candida spp. (46%), Aspergillus spp. (18%), Rhizomucor 
spp. (7%), Fusarium spp. (5%) and Lichtheimia spp. (4%).
Out of 90 clinical specimens, in which fungal pathogens were present, ITS sequence analysis revealed species 
identifications in 59 specimens and led to identification on genus level in 19 specimens. Twelve samples did not 
show any relevant fungal identification by ITS sequencing (Table 2) and were therefore assessed negative. In con-
trast, 18S rDNA sequencing revealed 13 species identifications and 75 genus identifications. Two samples did not 
show any relevant fungal identification by 18S rDNA sequencing (Table 2) and were assessed negative.
Overall, the concordance of 18S rDNA RT-PCR and ITS PCR results for the diagnosis of fungal infections 
was 94% (Table 1). Sensitivity of the 18S rDNA RT-PCR was higher compared to ITS PCR, while specificity was 
equal among both methods using a composite diagnostic measure combining clinical and microbiological data 
as gold standard.
Diagnostic performance of 18S rDNA RT-PCR compared to culture. Traditionally, conventional 
culture is used for the microbiological diagnosis of fungal infections. For 151/233 clinical specimens culture and 
18S rDNA RT-PCR results were available. 104/151 specimens (69%) concordantly tested negative, and 34 speci-
mens (22%) tested positive by culture and 18S rDNA sequencing. Thirteen of 151 (9%) clinical specimens showed 
discrepant results between both methods (Tables 3 and 4).
Among the 151 analysed specimens, we did not observe any culture positive and PCR negative samples, but 
13 specimens from “confirmed fungal infection” cases were 18S rDNA RT-PCR positive and culture negative 
(Table 4). Therefore, sensitivity of the 18S rDNA RT-PCR was higher compared to culture, while specificity was 
equal among both methods using a composite diagnostic measure combining clinical and microbiological data 
as gold standard. Overall, we found a concordance of 91% between 18S rDNA RT-PCR and culture results for the 
diagnosis of fungal infections (Table 3).
Discussion
Early diagnosis of fungal infection is critical for effective treatment. There are many impediments to classical diag-
nostic methods like culture and microscopy such as increasing diversity of fungal pathogens, diminishing num-
ber of experienced clinical mycologists, costs and long time to result. Molecular methods offer the opportunity for 
sample 
number clinical specimens
direct 
microscopic 
examination
species 
identification 
using culture
species 
identification 
using ITS PCR
Ct value in 
18S rDNA 
RT-PCR
Species 
identification using 
18S rDNA RT-PCR clinical information
1 biopsy nd nd negative 32.2 Aspergillus sp. clinical suspicion of invasive aspergillosis
2 cornea negative negative negative 34.3 Fusarium sp. keratitis, clinical suspicion of invasive mycosis
3 paraffin section from epipharynx nd nd negative 34.0 Malassezia sp. osteomyelitis, invasive mycosis
4 paraffin section from sinus maxillaris nd nd negative 33.3 Malassezia sp. osteomyelitis, invasive mycosis
5 paraffin section from the upper lobe of the lung nd nd negative 35.1 Rhizopus sp.
pulmonary mycetoma, clinical suspicion of 
invasive mucormycosis
6 paraffin section from epipharynx positive nd negative 34.0 Rhizopus sp. pulmonary zygomycosis, clinical suspicion of mucormycosis
7 biopsy from the sinus positive negative negative 31.8 Aspergillus sp. chronic fungal sinusitis, clinical suspicion of invasive aspergillosis
8 cornea negative negative negative 31.1 Fusarium sp. keratitis, clinical suspicion of invasive mycosis
9 blood (EDTA) nd negative negative 30.0 Rhizomucor pusillus clinical suspicion of invasive mycosis
10 blood (Citrate) nd negative negative 33.6 Cryptococcus sp. clinical suspicion of invasive mycosis
11 bronchoalveolar lavage negative negative negative 34.8 Pneumocystis jirovecii
clinical suspicion of pneumocystis 
pneumonia in immunocompromised 
patient
12 paraffin section from the lung nd negative negative 32.9 Rhizomucor pusillus invasive mucormycosis of the lung
13 bronchoalveolar lavage negative negative Aspergillus sp. 37.0 negative clinical suspicion of invasive aspergillosis
14 abscess negative negative Candida albicans 36.8 negative abscess, invasive mycosis
Table 2. Clinical specimens (N = 14) that showed discrepant results in fungal identification by ITS PCR and 
18S rDNA RT-PCR. nd = not done.
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determining the presence and diversity of fungi in clinical specimens and can readily be integrated in strategies 
for full lab automation.
In this study, a set of well characterized clinical samples was used to evaluate a molecular based algorithm for 
fast and reliable fungal detection and identification. The proposed diagnostic workflow includes automated DNA 
extraction and high throughput screening of clinical specimens by 18S rDNA RT-PCR (batches of 24 clinical 
samples can be analyzed per run). This procedure offers rapid diagnosis of fungal infections (<4 hours to identify 
a clinical sample as negative and <8 hours to obtain species identification by 18S rDNA sequencing). The diag-
nostic workflow does not require time consuming semi-nested PCRs and CleanGel analysis for visualization of 
ITS PCR products. An 18S rDNA specific fungal probe is used in the RT-PCR, and amplification products can 
be sequenced directly if a Ct value is obtained in RT-PCR. This is particularly useful as the majority of specimens 
that have been sent to our diagnostic laboratory over the last years (2013 to 2017) tested negative by culture and/
or ITS PCR. Rapidly receiving a negative test result may assist the treating physicians in their decision to stop 
antifungal therapy that can have severe adverse effects (e.g. hepatoxicity and nephrotoxicity) for the patient14.
Based on species discrimination across the fungal kingdom, ITS is generally superior to the 18S rRNA 
gene, allowing higher phylogenetic resolution regarding species identification of some genera, like Candida 
and Aspergillus. However, the increased phylogenetic resolution is accompanied by lower sensitivity in fungal 
detection (12 clinically confirmed fungal infection cases missed by ITS PCR). In fact, the FungiQuant® primer/
probe set used in this study was designed in silico to completely cover the 18S rDNA target region of most 
fungal phyla (Saccharomycotina, Taphrinomycotina, Pezizomycotina, Mucoromycotina, Pucciniomycotina, 
Agaricomycotina)15. This allows sensitive detection of a diverse range of fungal species and high amplification 
efficiencies.
Empiric treatment of fungal infections like aspergillosis, cryptococcosis, mucormycosis, and invasive candida 
infections normally doesn’t require species specific identification16. A more crucial factor is the rapidity with 
which guided antifungal treatment can be administered. If phylogenetic resolution of the 18S rDNA gene is not 
sufficient for species level identification, a second PCR that targets other fungal marker genes17 can be addition-
ally used in a routine diagnostic testing algorithm.
clinical and microbiological data
positive negative
18S rDNA RT-PCR
positive 47 0
negative 0 104
Culture
positive 34 0
negative 13 104
Table 3. Comparison of fungal identification by 18S rDNA RT-PCR and culture (N = 151) applying a gold 
standard that combines clinical and microbiologal data.
no clinical specimens
direct 
microscopic 
examination
species 
identification 
using culture
species identification 
using ITS PCR
Ct value in 
18S rDNA 
RT-PCR
species identification 
using 18S rDNA RT-
PCR clinical information
1 biopsy from sinus maxillaris positive negative Aspergillus fumigatus 32.0 Aspergillus sp.
chronic fungal sinusitis, clinical suspicion 
of invasive aspergillosis
2 wound secretion positive negative Aspergillus fumigatus 31.7 Aspergillus sp. abscess in the nose, clinical suspicion of invasive aspergillosis
3 wound secretion negative negative Aspergillus fumigatus 30.6 Aspergillus sp. chronic fungal sinusitis, clinical suspicion of invasive aspergillosis
4 biopsy from sinus maxillaris positive negative Aspergillus fumigatus 30.0 Aspergillus sp.
chronic fungal sinusitis, clinical suspicion 
of invasive aspergillosis
5 deep wound negative negative Candida albicans 29.6 Candida sp. endograft infection after EVAR
6 biopsy from sinus negative negative Lichtheimia corymbifera 26.6 Lichtheimia corymbifera chronic fungal sinusitis
7 deep wound of the skin negative negative Malassezia sympodialis 26.3 Malassezia sp. invasive mycosis of the skin
8 biopsy from liver negative negative Rhizomucor sp. 34.6 Rhizomucor pusillus clinical suspicion of mucormycosis
9 biopsy from ethmoid positive negative Scedosporium sp. 26.1 Scedosporium sp. ethmoidectomy after chronic sinuitis, invasive mycosis
10 cornea negative negative negative 34.3 Fusarium sp. keratitis, clinical suspicion of invasive mycosis
11 biopsy from the sinus positive negative negative 31.8 Aspergillus sp. chronic fungal sinusitis, clinical suspicion of invasive aspergillosis
12 cornea negative negative negative 31.1 Fusarium sp. keratitis, clinical suspicion of invasive mycosis
13 blood (EDTA) nd negative negative 30.0 Rhizomucor pusillus clinical suspicion of invasive mycosis
Table 4. Clinical specimens (N = 13) that showed discrepant results in fungal identification by culture and 18S 
rDNA RT-PCR.
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Overall, 18S rDNA RT-PCR amplification showed higher efficiency and revealed better results than ITS PCR. 
ITS sequencing often revealed ambigious sequences that could not be interpreted. Therefore, 117 sequencing 
reactions were necessary to obtain 78 interpretable Sanger electropherograms. In contrast, sequencing of 18S 
rDNA always revealed interpretable electropherograms, which led to reduced workload and costs. 18S rDNA 
sequencing also showed higher sensitivity than ITS PCR as ITS PCR did not detect fungal pathogens in 12 clinical 
specimens. ITS PCR did not identify Rhizomucor sp. and Rhizopus sp. in 4 clinical specimens, which is problem-
atic as mucormycosis is a severe disease associated with a high mortality rate18. Therefore, sensitive detection of 
mucorales is a necessary requirement for molecular assays. ITS PCR failed to provide a species identification in 
one case of Pneumocystis jirovecii associated pneumonia. Pneumocystis jirovecii causes life-threatening infection, 
mainly in immunocompromised patients19. Lower diagnostic sensitivity of the ITS PCR may also explain the 
negative results from paraffin sections (N = 5). Though fixatives do not physically degrade nucleic acids per se, 
they reduce the amplifiable quantity of available DNA in clinical specimens20.
Two clinical specimens were ITS PCR positive and 18S rDNA RT-PCR negative. Both specimens showed a Ct 
value > 36 in the 18S rDNA RT-PCR indicating low amounts of available DNA in the clinical specimen. Indeed, 
review of the original silver stained CleanGel showed rather weak PCR bands in the CleanGel. If the DNA yield is 
low in the clinical specimen, prolonged freezing and thawing of genomic DNA may lead to progressive DNA deg-
radation21, and it may potentially explain the inability to identify the fungal pathogens by 18S rDNA sequencing.
One requirement for using molecular based fungal identification in an accredited diagnostic laboratory is 
standardized 18S rDNA sequence identification. Generally, 18S rDNA sequence data can be used to search pub-
lic databases, such as GenBank, using the web-based BLASTn algorithm. Unfortunately, the uncurated nature 
of Genbank has always been problematic for fungal identification, and therefore sequence analysis should be 
performed with extreme caution owing to the high frequency of erroneous deposits22. This has led to the develop-
ment of both commercially and publicly curated, closed databases like SmartGene (SmartGene GmbH, Lausanne, 
Switzerland), RipSeq (Pathogenomix, Santa Cruz, USA) or the SILVA ribosomal RNA database project23. We 
used two SmartGene databases, the ITS SmartGene IDNS database that contains at present 413,375 curated 
entries (from approximately 777,690 available ITS sequences in Genbank) and the 18S SmartGene IDNS data-
base that contains at present 47,592 curated entries (from approximately 230,000 available “true” 18S sequences 
in Genbank). Only sequences of high quality (e.g. good coverage, well annotated, only a few Ns and gaps in the 
sequence) are accepted in these SmartGene IDNS databases to allow standardized, reproducible and accurate 
identification of fungal pathogens.
Conclusions
The goal of this study was to evaluate a diagnostic workflow for fungal identification using automated DNA 
extraction and 18S rDNA RT-PCR, followed by SANGER sequencing and species identification using the 
SmartGene IDNS database. We found high concordance between 18S rDNA RT-PCR, ITS PCR and culture, 
respectively for the diagnosis of fungal infections. Compared to ITS PCR and culture, 18S rDNA RT-PCR has the 
advantages of higher sensitivity, faster processing (<1 working day) and prospect for a high degree of laboratory 
automation.
Materials and Methods
Study design, clinical specimens and medical record review. Clinical samples were sent to the 
Institute of Medical Microbiology from secondary and tertiary hospitals from the Zurich metropolitan area 
for fungal identification by culture and/or ITS PCR. The specimens were mainly from normally sterile body 
sites (fresh biopsies (N = 100), punctates and deep wound secretions (N = 66), paraffin sections (N = 17), whole 
blood (N = 9), CSF (N = 7), bone marrow (N = 3), bones (N = 3)) but also from the eye and from the ear-nose-
throat area (respiratory materials (N = 28) such as bronchoalveolar lavage, respiratory swabs, sputum, tracheal, 
broncheal and nasopharyngeal secretions). The retrospective study included 233 clinical specimens from unique 
patients analysed between 2013 and 2017 at our ISO accredited diagnostic laboratory. Diagnosis of fungal infec-
tion was done combining underlying disease and disease history of the patient, clinical course of disease and 
interventions, clinical signs and symptoms of inflammation, additional diagnostics if available (such as radiology 
and pathology reports), and microbiological findings (microscopy, culture, PCR results, detection of bacterial 
or viral pathogens) including detailed consultations with the treating physicians. Therefore, all included patient 
samples in the retrospective study could be categorized as “confirmed fungal infection” or “no fungal infection”.
Phenotypic methods. Clinical specimens were analysed by culture methods and microscopy for the 
presence of fungi as described previously24–26. Briefly, specimens were cultured on general mycology media 
(Sabouraud dextrose agar containing gentamicin and chloramphenicol, and brain heart infusion (BHI) agar; 
Becton Dickinson AG, Allschwil, Switzerland) and on fungal selective media (Chromagar, and Mycosel; Becton 
Dickinson AG) for a maximum of 3 weeks at 25 °C and were regularly examined for growth by eye. Subcultures 
for identification were done as follows: (i) Aspergillus spp. on malt yeast agar6 at 25, 35, and 42 °C; (ii) mucor-
ales on potato carrot agar at 25, 37, 40, 45, 50, and 56 °C; (iii) all other molds on Sabouraud dextrose agar con-
taining gentamicin and chloramphenicol at 25 and 35 °C and on Mycosel and potato carrot agar, both at 25 °C 
(temperatures as routinely used in our clinical laboratory). Phenotypic identification was based on macro- and 
micro-morphological criteria26.
Genotypic methods. DNA from clinical specimens was extracted on the EZ1 Advanced XL (QIAGEN, 
Hombrechtikon, Switzerland) using the EZ1 DNA Tissue Kit (QIAGEN, Hombrechtikon, Switzerland), following 
the manufacturer’s instructions. A process control was included (i.e. water sample) in each analysis to exclude 
fungal DNA contamination in the DNA extraction chemistry, buffers and PCR reagents.
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PCR amplification of the ITS region was performed using ITS1 and ITS412 as described previously9. 
Amplification products were visualized by polyacrylamide gel electrophoresis (CleanGel 10% 52S, ETC GmbH) 
combined with silver staining. Subsequently, a semi-nested PCR was performed and ITS PCR products were 
purified with the QIAquick PCR purification kit (Qiagen, Hombrechtikon, Switzerland). ITS PCR products 
were sequenced with primer ITS4 and ITS312 using the BigDye kit (Life Technologies, Zug, Switzerland) and 
an automated DNA sequencer (ABI Prism 3130 Genetic Analyzer; Life Technologies, Zug, Switzerland). Fungal 
identification of ITS PCR products was done using the ITS SmartGene IDNS custom platform, following the 
identification guidelines from Ciardo et al.24.
DNA from the clinical specimens (N = 233) was retrospectively analysed by 18S rDNA RT-PCR. For the 18S 
rDNA RT-PCR, 5 µl of extracted DNA was added to a mixture consisting of 8.5 µl Roche water (Roche, Rotkreuz, 
Switzerland), 4 µl of a LightCycler® DNA multiplex master mix (Roche), 0.5 µM of each FungiQuant® primer 
and 0.25 µM of the FungiQuant® probe15. Cycling parameters included an initial denaturation for 5 min at 95 °C, 
followed by 45 cycles of 5 sec at 95 °C, 15 sec at 60 °C and 15 sec at 72 °C. Subsequently, the 18S rDNA RT-PCR 
products were purified with the QIAquick PCR purification kit, and sequenced using the BigDye kit and an 
automated DNA sequencer (ABI Prism 3130-Genetic Analyzer; Life Technologies, Zug, Switzerland). Sanger 
electropherograms were visually examined (regularity of base spacing, distribution of peak heights, occurrence 
and height of minor background peaks). Any part of the electropherogram that showed irregularities (e.g. high 
background noise, irregular base spacing and peak height distributions) was excluded from the reported result. 
Accurate fungal identification was achieved by analysing sequences with a quality score >20 (“>Q20”) that cov-
ered at least 300 bp of the respective fungal 18S rRNA gene in the 18S SmartGene IDNS custom platform. Species 
and genus level identification was done following the criteria by Ciardo et al.24.
A major disadvantage of PCR in comparison to culture is the frequent contamination of reagents and mate-
rials with traces of fungal DNA27. We used three criteria to uncover environmental contamination and to strictly 
categorize samples as negative: (1) no distinct ITS PCR fragment in the CleanGel or no PCR amplification with a 
Ct value in the 18S rDNA RT-PCR, (2) fungal identification in a clinical specimen identical to contamination in 
the process control, (3) identification of a known environmental contaminant.
Statistics. A synopsis of clinical findings (disease history, clinical picture) and laboratory results (microscopy, 
ITS PCR, culture) including consultation with the treating physician was used as gold standard to categorize 
patients into “clinically confirmed fungal infection” or “no fungal infection” cases. On the basis of this composite 
diagnostic measure, we used the 2 × 2 contingency table to calculate the agreement between culture, ITS PCR and 
18S rDNA RT-PCR results28,29.
Ethics statement. The study was conducted according to good laboratory practice and in accordance with 
the Declaration of Helsinki and national and institutional standards. The act on medical research involving 
human subjects does not apply to this study. In this study, solely extracted DNA from clinical specimens an 
anonymized health realted data were used, therefore no consent from the ethics committe was required.
Availability of data. The datasets generated and analysed during the current study are available from the 
corresponding author on reasonable request.
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